Wnioski: Wykazano, że leczenie metforminą w dawce 1500 mg przez okres sześciu miesięcy skutkuje poprawą profilu lipidowego u pacjentek z PCOS i prawidłową należną masą ciała. Zaobserwowano istotny spadek wartości cholesterolu LDL i triglicerydów po leczeniu metforminą.
Introduction PCOS (polycystic ovary syndrome) is a common endocrine disorder among women during their reproductive age [1] . The diagnosis of PCOS is made according to the following criteria: oligoovulation or anovulation, clinical or biochemical features of hyperandrogenism, the polycystic ovary in the ultrasound [2] . To diagnose PCOS the woman has to meet at least two of them and other causes of hyperandrogenemia have to be excluded [2] . The frequency of PCOS among women in reproductive age is 4-10% [3] [4] [5] . The PCOS treatment depends on clinical symptoms and whether the woman wants to get pregnant [6] . Nevertheless, the therapy should include minimizing the risk of further complications [7] [8] [9] [10] . The metabolic syndrome occurs more frequently in PCOS women than among age-matched women in the general population [7] . Still, after stratification, by both age and BMI, the metabolic syndrome appeared more frequently in PCOS women [7] . Low HDL-C levels have been reported with the prevalence up to 91% in PCOS women [7, 8] . PCOS and metabolic syndrome shares some clinical features and their consequences. Because of that PCOS patients are at higher risk of cardiovascular disease. It is estimated that the prevalence of metabolic syndrome among PCOS women is 43-46% [7, 9] . Patients with PCOS had higher risk of type 2 diabetes [9] , coronary heart disease, stroke [10] and myocardial infarction [11, 12] . The biguanide metformin is a first-line pharmacotherapy in type 2 diabetes [13] . It is used in type 2 diabetes treatment since 1957 in Europe [14] . Nowadays metformin is also used in PCOS, pre-diabetes, and in patients with type 1 diabetes and insulin resistance [15, 16] . Another beneficial effects of metformin in clinical practice are considering, e.g. in gestational diabetes, in cancer treatments, in lipids lowering therapy or in prevention of cardiovascular diseases [15] . Some recent studies showed that metformin administration results in decrease in low-density lipoprotein cholesterol (LDL--C) level, total cholesterol and triglycerides [17] [18] [19] [20] , although the review showed that metformin has no effect on serum cholesterol or triglycerides [21] . A meta-analysis of randomized controlled trial reported that metformin administration had no effect on cholesterol, LDL-C, HDL-C levels but had a significant impact on serum triglycerides level compared to placebo [22] .
There is a growing concern on impact of metformin on lipids. We aimed to evaluate the effectiveness of metformin therapy on serum lipids in lean PCOS women.
Materials and Methods
A retrospective study was performed to assess the metformin influence on lipid profiles in lean PCOS patients. Thirty two women with polycystic ovarian syndrome were enrolled in the study. The diagnosis of PCOS among all examined patients was based on the Androgen Excess Society criteria [23] . We included patients with phenotype of free androgen index (FAI) only greater than or equal to 5. Hyperprolactinemia, androgen secreting tumors, Cushing's disease, congenital adrenal hyperplasia were excluded based on clinical and laboratory data.
The mean age of study population was 28 years (25-31 years). All patients have BMI (body mass index) within the normal range (18.5-24.9 kg/m²). All subjects had normal renal and hepatic function and had not received any medication for at least six months before the study. Patients who showed evidence of thyroid dysfunction, diabetes mellitus, cardiovascular diseases, hypertension or other internal pathologies were excluded from the study.
Each patient underwent a full clinical evaluation. Fasting blood samples were collected at 8 am from a forearm vein between 1-5 day of menstrual cycle. The following parameters were measured: luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone, trijodothyronin (FT3), thyroid stimulating hormone (TSH), thyroxin (FT4), sex hormone binding globulin (SHBG), all according to the routine methods. Free testosterone was calculated by using FAI ratio-the total testosterone level (nmol/l) was divided by the SHBG level (nmol/l) and then multiplying by a 100. The clinical characteristic of study population was presented in Table I .
All patients were treated with metformin 1500 mg daily, in three divided doses, for 6 months.
Collected data included lipids values measured before and after 6 months of metformin administration. Both total cholesterol and HDL-cholesterol concentrations were measured directly. The concentrations of LDL cholesterol were calculated according to the method of Friedewald et al. [24] : LDL cholesterol=total cholesterol--HDL cholesterol-(triacylglycerol/5).
The study was performed in the Department of Gynecological Endocrinology, Jagiellonian University Hospital, Cracow, Poland.
Statistical analysis
Clinical and laboratory parameters, expressed on continuous scale, were presented as means with standard deviations. Data did not present any significant outliers. Kolmogorov-Smirnov test revealed a normal distribution of data. Differences in lipid profiles pre-and post-metformin intervention were analyzed using paired t--tests. Statistical analysis was made using Statistica 12 (Statsoft, Tulsa, OK, USA). Pearson were used to asselation between.
Results
Serum lipids values at the beginning of the study and after 6 months metformin therapy were presented in Table II In lean patients with PCOS we observed statistically significant lower LDL-C levels (4.16±0.79 mmol/l vs 3.4±0.86 mmol/l, p<0.05) and lower triglycerides levels (1.8±0.53 mmol/l vs 1.12±0.64 mmol/l, p<0.05) after treatment with metformin. There was also an increase in HDL values and a decrease in total cholesterol values, but these changes were not statistically significant (1.5±0.71 mmol/l vs 1.71±0.69 mmol/l, p=0.09; 5.87±0.92 mmol/l vs 5.69±0.97 mmol/l, p=0.11).
Discussion
Our study showed that treatment of 1500 mg metformin for six months among PCOS women result in improvement in serum lipids. We observed a significant decrease in LDL-C and triglycerides values after metformin treatment. Changes in HDL values and total cholesterol values were not statistically significant.
There are some studies on the influence of metformin on serum lipid profile but the results remain inconclusive. Mhao et al. in their randomized control trial study (RTCs) also showed that metformin treatment in dose of 500 mg twice daily increase HDL-C and decrease triglycerides levels [25] . Result of analysis of 2372 studies and 12 RCTs presented that metformin treatment and lifestyle intervention versus lifestyle intervention alone or with placebo did not differ in lipids levels in PCOS women [26] . Some studies showed a beneficial influence of metformin therapy on lipid profiles [27] [28] [29] [30] , some did not [31] [32] [33] showed increased HDL-C [33] , while Onalan et al. reported decreased triglycerides levels after metformin therapy [34] . Some studies showed improvement in metabolic profile only in obese PCOS women [35, 36] . Sahin et al. presented that metformin therapy in lean patients with PCOS has no beneficial effect on lipid profiles and cardiovascular risk factor [37] . The baseline characteristics of patients might play a role in effectiveness of metformin therapy. Inconsistence results regarding the effect of metformin on lipid profiles in PCOS women can result from differences between study populations (BMI, insulin resistance, baseline lipids levels), doses and length of metformin treatment. The dosage and duration of therapy varied between studies, e.g. women received 500 mg of metformin over 90 days [30] , 500 mg of metformin three times a day for 3 months [27] , 500 mg of metformin for 6 months [38] , 500 mg of metformin twice a day and the lipids were assessed after 3 and 6 months of the therapy [32] . Studies with long follow-ups are needed to assess the long-term effects of metformin on lipid profile. It is of interest whether longer therapy or higher dose of metformin result in greater improvement of lipid profiles in comparison to lower dose of metformin or short-term therapy. It is unknown whether continuation of metformin therapy is needed to maintain beneficial effects of metformin on lipid profile.
The main limitation of the present study is the small number of patients investigated. In our opinion larger prospective trials are needed to test the hypothesis that metformin might have an beneficial impact on serum lipid profile in PCOS women.
Conclusion
Our study showed that therapy at daily doses of 1500 mg metformin for six months among lean PCOS women resulted in improvement in serum lipid profiles. We observed a significant decrease in LDL--C and triglycerides values after metformin treatment. This is of high importance to confirm whether metformin ameliorate or nor lipids in PCOS women because of possible clinical implications. Well-designed, randomized control trials should be conducted among numerous population of PCOS women.
